Ultimately, LIGHT exemplifies the complexity of immune regulation in IBD, and successful clinical translation will require not only innovative drug design but also a nuanced understanding of the contextual signals that shape LIGHT’s activity, enabling the development of strategies that selectively modulate the pathway to restore immune homeostasis without compromising its protective functions. Here, TNFSF14 is linked to inflammatory bowel disease.